Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004
Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005
Treatment of pulmonary hypertension (PH) and sickle cell disease (SCD) with sildenafil (SILD) therapy (walk-phasst): interim report Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009
Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Prediction of effects of calcium channel blockers (CCB) on hypoxic pulmonary hypertension (HPH) due to COPD Source: Eur Respir J 2003; 22: Suppl. 45, 268s Year: 2003
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007
Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016 Year: 2017
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007
Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005